Tukysa
Tukysa ingredients
| Active ingredient | Strength |
|---|---|
| Tucatinib | 50 mg/1, 150 mg/1 |
What Tukysa is used for
The FDA lists the approved uses on the official label (below). In the EU, tucatinib is approved as Tukysa for:
Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Tukysa
- Generic name
- Tucatinib
- Made by
- SEAGEN INC.
- Forms
- Tablet
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA213411
- On the US market since
- 2020
Official information
- MedlinePlus drug information (search for Tucatinib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Tukysa?
Tukysa (Tucatinib) is a cancer medicine made by SEAGEN INC., approved by the US FDA.
What are the ingredients of Tukysa?
Tukysa contains Tucatinib (50 mg/1, 150 mg/1).
Is Tukysa approved in Europe?
The same active substance is approved in the EU as Tukysa.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA